Policies to promote affordability and access across the life cycle of costly new drugs
- PMID: 41218975
- PMCID: PMC12599526
- DOI: 10.1136/bmj-2025-086516
Policies to promote affordability and access across the life cycle of costly new drugs
Abstract
Strategic collaboration among countries and sectors on policies that prioritise equity throughout the full medicine life cycle could make innovative therapies more affordable and accessible globally, argue Krista Kruja and colleagues
Conflict of interest statement
Competing interests: We have read and understood BMJ policy on declaration of interests and declare the following: KK, JMF, MH, ZK, and SM received financial support from WHO Europe to prepare the Oslo Medicines Initiative Technical Reports. BR established the Melanoma Patient Network Europe, the activities of which are financed by balanced support from diverse pharmaceutical and diagnostic companies. In the past two years, BR has received consultancy fees from Illumina, MSD Sweden, Novartis, Roche, and Sobi.
References
-
- Colombatti R, Birkegård C, Medici M. PB2215: global epidemiology of sickle cell disease: a systematic literature review. HemaSphere 2022;6(suppl):2085-6. 10.1097/01.HS9.0000851688.00394.f4. - DOI
-
- World Health Organization. The Oslo Medicines Initiative. 2025. https://www.who.int/europe/initiatives/the-oslo-medicines-initiative
-
- World Health Organization. Seventy-eighth World Health Assembly. 2025. https://www.who.int/about/governance/world-health-assembly/seventy-eighth
Publication types
LinkOut - more resources
Full Text Sources